latest news releases from the newsroom
Unicorp Signs Binding Letter of Intent to Acquire the 10-Year Exclusive License For Proprietary Vibroseismic Impact Technology
HOUSTON, Dec. 1, 2004 (PRIMEZONE) -- Unicorp, Inc. (Pink Sheets:UCPI) announced today that it has signed a binding letter of intent to acquire the exclusive 10 year U.S. license for the use of this proprietary Vibroseismic Impact Technology. This binding letter of intent is subject to Unicorp's satisfaction of increased production from its South Texas oil field project, which is currently being treated and the execution of a definitive agreement within six months of the final test results. Results for the South Texas field are expected in mid-January 2005.
ASM International NV
ASM International N.V. Announces Private Placement of U.S. $125 Million Convertible Subordinated Notes
BILTHOVEN, The Netherlands, Dec. 1, 2004 (PRIMEZONE) -- ASM International N.V. (Nasdaq:ASMI) (Euronext Amsterdam:ASM) announced today the private placement of U.S. $125 million of 4.25% convertible subordinated notes due 2011. The notes are convertible into ASMI common shares at a conversion price of U.S. $20.82 per share, which is equivalent to a conversion rate of 48.0307 shares for each U.S. $1,000 principal amount of notes and represents a 35% premium over the closing sale price of ASM International common shares on the Euronext Amsterdam stock exchange on December 1, 2004. Initially, cash will be delivered in lieu of a portion of the common shares to be delivered upon conversion in an amount equal to the principal amount of the notes converted (or, if less, the conversion value). Upon receipt by ASM International of shareholder approval to issue additional common shares, only common shares will be delivered upon conversion of the notes. Prior to the time of shareholder approval, the maximum number of common shares issuable upon conversion of each U.S. $1,000 principal amount of notes in excess of the cash portion will be 34 or, if the initial purchasers' option to purchase additional notes is fully exercised, 28.
Coastal Holdings, Inc.
Coastal Holdings, Inc. Retracts from the Acquisition of an Equity Interest in Efoora, Inc.
HOUSTON, Dec. 1, 2004 (PRIMEZONE) -- Coastal Holdings, Inc. (Pink Sheets:CSJJ), a leading edge global technology holding company, announced today that it has retracted from its prior decision to acquire an equity interest in Efoora, Inc. Based on further analysis, CSJJ has concluded that at the present time an investment in Efoora is not in the best interests of the Company and its shareholders. The original decision was based on the advice of the Legal Department and failed to take into account pertinent information on Efoora that was exposed to CSJJ by several of its major shareholders.
Teen Pop Group "TGK" Set To Release Highly Anticipated Album
LOS ANGELES, Dec. 1, 2004 (PRIMEZONE) -- KidSational, Inc. (Pink Sheets:KDSC) announces that the Teen Pop Group, TGK is set to release their debut untitled album during the First Quarter of 2005 on KidSational Records. The first single "HOTT" is slated to be officially released in mid-January and will garner early airplay at mid-market radio stations on both the East and West Coasts.
Software International Inc.
Knobias Initiates Research Coverage of Software International, Inc.
SOMERSET, N.J., Dec. 1, 2004 (PRIMEZONE) -- Knobias.com, L.L.C. and Software International, Inc. (Pink Sheets:SWII) announced today that the Knobias Research Report and an up close interview with CEO Suneel Sawant & CTO Ninad Panse would be made available for free to members of the www.siliconinvestor.com and www.investorshub.com online communities. Investor's Hub boasts nearly 1.5 million page views per day alone and has more of a smallcap focus while Silicon Investor tends to be more blue chip in flavor and is the better-known brand.
Maxim Pharmaceuticals Announces Publication of Two Manuscripts Describing Pre-Clinical Anticancer Activity in Novel Class of Microtubule Inhibitors
SAN DIEGO, Dec. 1, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) announced today the publication of two manuscripts in the Journal of Molecular Cancer Therapeutics (Mol Cancer Ther 2004 3: pp. 1365-1374 and 1375-1384) describing Maxim's MX116407 anticancer drug candidate as part of a novel class of microtubule inhibitors with vascular targeting activity. The manuscripts characterize MX116407 as a potent caspase activator with strong antitumor activity in pre-clinical in vitro and in vivo studies. MX116407 appeared highly effective in mouse tumor models, producing tumor necrosis at doses that correspond to only 25% of the maximum tolerated dose. Moreover, in combination treatment, MX116407 significantly enhanced the antitumor activity of the chemotherapeutic agent cisplatin, resulting in tumor-free animals.